Exclusive Summary

• - First-in-class/one of the very few TRAIL-pathway apoptosis inducers, approved in China in 2024 and listed in NRDL, offering first-mover and real-world evidence advantages.
• - Targets large unmet post-line oncology populations (a substantial share of the ~20M annual new cancer cases globally), with named-patient/special access already validated (Singapore case).
• - No marketed in-class competitors; best positioned as a mechanism-complementary partner to PD-1s, chemotherapy and TKIs for combination regimens.
• - Ready Chinese CTD with rapid conversion to English eCTD; NMPA approval and NRDL status support robust CMC and supply, facilitating reliance pathways in ASEAN/MENA/LATAM.
• - NRDL-anchored competitive pricing plus China manufacturing cost advantage enable a "high value, novel mechanism" pricing strategy ex-China.

Asset Materials

Contact Us for Full Materials